<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">sechenov</journal-id><journal-title-group><journal-title xml:lang="en">Sechenov Medical Journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Сеченовский вестник</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2218-7332</issn><issn pub-type="epub">2658-3348</issn><publisher><publisher-name>Сеченовский Университет</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">sechenov-805</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL CHEMISTRY</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКАЯ ХИМИЯ</subject></subj-group></article-categories><title-group><article-title>THE STUDY OF INTESTINAL PERMEABILITY IN VITRO ON A MONOLAYER OF EPITHELIAL CACO-2 CELLS (REVIEW)</article-title><trans-title-group xml:lang="ru"><trans-title>ИЗУЧЕНИЕ КИШЕЧНОЙ ПРОНИЦАЕМОСТИ В УСЛОВИЯХ IN VITRO НА МОНОСЛОЕ ЭПИТЕЛИАЛЬНЫХ КЛЕТОК САСО-2 ( ОБЗОР )</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шохин</surname><given-names>И. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Shokhin</surname><given-names>I. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>И.Е. Шохин, к.фарм.н., ассистент кафедры фармацевтической и токсикологической химии</p></bio><bio xml:lang="en"><p>I.E. Shokhin, PhD, assistant of the chair of pharmaceutical and toxicological chemistry</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Раменская</surname><given-names>Г. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ramenskaya</surname><given-names>G. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Галина Владиславовна Раменская, д.фарм.н., профессор, заведующая кафедрой фармацевтической и токсикологической химии, директор НИИ фармации8 (495) 691–13–92</p><p>119019, г. Москва, ул. Никитский бульвар, д. 13</p></bio><bio xml:lang="en"><p>G.V. Ramenskaya, Doctor of pharmacy, prof., head of the chair of pharmaceutical and toxicological chemistry, director of the Research institute of pharmacy</p></bio><email xlink:type="simple">ramenskaia@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кулинич</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kulinich</surname><given-names>Y. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ю.И. Кулинич, аспирантка кафедры фармацевтической и токсикологической химии</p></bio><bio xml:lang="en"><p>Yu.I. Kulinich, post-graduate student of the chair of pharmaceutical and toxicological chemistry</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савченко</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Savchenko</surname><given-names>A. Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>А.Ю. Савченко, к.м.н., заместитель директора по инновационному развитию НИИ фармации</p></bio><bio xml:lang="en"><p>A.Yu. Savchenko, PhD, deputy director of innovative development of the Research institute of pharmacy</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Первый МГМУ им. И.М. Сеченова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>First MSMU named after I.M. Sechenov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>30</day><month>09</month><year>2012</year></pub-date><volume>0</volume><issue>3</issue><fpage>31</fpage><lpage>35</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Shokhin I.E., Ramenskaya G.V., Kulinich Y.I., Savchenko A.Y., 2012</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="ru">Шохин И.Е., Раменская Г.В., Кулинич Ю.И., Савченко А.Ю.</copyright-holder><copyright-holder xml:lang="en">Shokhin I.E., Ramenskaya G.V., Kulinich Y.I., Savchenko A.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sechenovmedj.com/jour/article/view/805">https://www.sechenovmedj.com/jour/article/view/805</self-uri><abstract><p>This paper is devoted to the application of epithelial monolayer of human colon adenocarcinoma cells — Caco-2 for in vitro permeability evaluation of drugs. Main advantages of this biological model are described. General principles, approaches and methodology of Caco-2 permeability assay are defined. Correlation between human intestinal permeability in vitro and apparent permeability coefficient in vitro is indicated</p></abstract><trans-abstract xml:lang="ru"><p>Статья посвящена применению монокультуры клеток аденокарциномы толстого кишечника Caco-2 для оценки проницаемости лекарственных веществ in vitro. Описаны основные преимущества использования данной биологической модели. Приведены общие принципы, подходы и методология определения проницаемости на культуре клеток Сасо-2. Показана корреляция между значениями кишечной проницаемости, определенной в условиях in vivo, и результатами in vitro.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Клетки Сасо-2</kwd><kwd>проницаемость</kwd><kwd>абсорбция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Caco-2 cells</kwd><kwd>permeability</kwd><kwd>absorption</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Amidon G.L., Lennerlas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classifi cation: The correlation of in vitro drug product dissolution and in vivo bioavailability // Pharmaceutical Recearch. — 1995. — № 12. — P. 413–420.</mixed-citation><mixed-citation xml:lang="en">Amidon G.L., Lennerlas H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classifi cation: The correlation of in vitro drug product dissolution and in vivo bioavailability // Pharmaceutical Recearch. — 1995. — № 12. — P. 413–420.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediaterelease, solid oral dosage forms. Technical Report Series, № 937, 40&lt;sup&gt;th&lt;/sup&gt; Report, Annex 8 of WHO Expert Committee on Specifi cations for Pharmaceutical Preparations. — World Health Organization (WHO), 2006.</mixed-citation><mixed-citation xml:lang="en">Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediaterelease, solid oral dosage forms. Technical Report Series, № 937, 40&lt;sup&gt;th&lt;/sup&gt; Report, Annex 8 of WHO Expert Committee on Specifi cations for Pharmaceutical Preparations. — World Health Organization (WHO), 2006.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kasim N.A., Whitehouse M., Ramachandran C. et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classifi cation // Molecular Pharmaceutics. — 2004. — Vol. 1. — № 1. — Р. 85–96.</mixed-citation><mixed-citation xml:lang="en">Kasim N.A., Whitehouse M., Ramachandran C. et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classifi cation // Molecular Pharmaceutics. — 2004. — Vol. 1. — № 1. — Р. 85–96.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J.-S., Mitchell S., Kĳ ek P. et al. The suitability of an in situ perfusion model for permeability determinations: utility for BCS Class I biowaiver requests // Molecular Pharmaceutics. — 2004. — Vol. 1. — № 1. — Р. 85–96.</mixed-citation><mixed-citation xml:lang="en">Kim J.-S., Mitchell S., Kĳ ek P. et al. The suitability of an in situ perfusion model for permeability determinations: utility for BCS Class I biowaiver requests // Molecular Pharmaceutics. — 2004. — Vol. 1. — № 1. — Р. 85–96.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man — Fact or myth // Pharmaceutical Research. — 1997. — Vol. 14. — № 6. — P. 763–766.</mixed-citation><mixed-citation xml:lang="en">Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man — Fact or myth // Pharmaceutical Research. — 1997. — Vol. 14. — № 6. — P. 763–766.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wu C.-Y., Benet L. Predicting drug disposition via application of BCS: Transport / absorption / elimination interplay and development of a biopharmaceutics drug disposition classifi cation system // Pharmaceutical Research. — 2005. — Vol. 22. — № 1. — Р. 11–23.</mixed-citation><mixed-citation xml:lang="en">Wu C.-Y., Benet L. Predicting drug disposition via application of BCS: Transport / absorption / elimination interplay and development of a biopharmaceutics drug disposition classifi cation system // Pharmaceutical Research. — 2005. — Vol. 22. — № 1. — Р. 11–23.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport // Advanced Drug Delivery Reviews. — 2001. — Vol. 46. — P. 27–43.</mixed-citation><mixed-citation xml:lang="en">Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport // Advanced Drug Delivery Reviews. — 2001. — Vol. 46. — P. 27–43.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Le Ferrec E., Chesne C., Artursson P. et al. In vitro models of the intestinal barrier. The report and recommendations of ECVAM workshop 46 // ATLA. — 2001. — Vol. 29. — P. 649–668.</mixed-citation><mixed-citation xml:lang="en">Le Ferrec E., Chesne C., Artursson P. et al. In vitro models of the intestinal barrier. The report and recommendations of ECVAM workshop 46 // ATLA. — 2001. — Vol. 29. — P. 649–668.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Shah P., Jogani V., Bagchi T., Misra A. Role of Caco-2 сell monolayers in prediction of intestinal drug absorption // Biotechnology Progress. — 2006. — Vol. 22. — № 1. — P. 186–198.</mixed-citation><mixed-citation xml:lang="en">Shah P., Jogani V., Bagchi T., Misra A. Role of Caco-2 сell monolayers in prediction of intestinal drug absorption // Biotechnology Progress. — 2006. — Vol. 22. — № 1. — P. 186–198.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lennernas H., Palm K., Fagerholm U., Artursson P. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells: In vitro and human jejunum in vivo // International Journal of Pharmaceutics. — 1996. — Vol. 127. — № 1. — P. 103–107.</mixed-citation><mixed-citation xml:lang="en">Lennernas H., Palm K., Fagerholm U., Artursson P. Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells: In vitro and human jejunum in vivo // International Journal of Pharmaceutics. — 1996. — Vol. 127. — № 1. — P. 103–107.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coeffi cients in human intestinal epithelial (Caco-2) cells // Biochemical and Biophysical Research Communications. — 1991. — Vol. 175. — № 3. — P. 880–885.</mixed-citation><mixed-citation xml:lang="en">Artursson P., Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coeffi cients in human intestinal epithelial (Caco-2) cells // Biochemical and Biophysical Research Communications. — 1991. — Vol. 175. — № 3. — P. 880–885.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dahan A., Miller J.M., Amidon G.L. Prediction of solubility and permeability class membership: Provisional BCS classifi cation of the world’s top oral drugs // AAPS J. — 2009. — Vol. 11. — № 6. — P. 740–746.</mixed-citation><mixed-citation xml:lang="en">Dahan A., Miller J.M., Amidon G.L. Prediction of solubility and permeability class membership: Provisional BCS classifi cation of the world’s top oral drugs // AAPS J. — 2009. — Vol. 11. — № 6. — P. 740–746.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. — U.S., Department of Health and Human Services, Food and Drug Administration (HHS-FDA), Center for Drug Evaluation and Research (CDER), 2000.</mixed-citation><mixed-citation xml:lang="en">Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. — U.S., Department of Health and Human Services, Food and Drug Administration (HHS-FDA), Center for Drug Evaluation and Research (CDER), 2000.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Соловьев А.И., Резников А.Г., Тарасенко Л.В., Маргитич В.М. Первый в Украине успешный опыт применения биовейвера для экспертной оценки лекарственного средства (Летромара) // Журнал АМН Украины. — 2006. — Т. 12. — № 4. — С. 781–794.</mixed-citation><mixed-citation xml:lang="en">Соловьев А.И., Резников А.Г., Тарасенко Л.В., Маргитич В.М. Первый в Украине успешный опыт применения биовейвера для экспертной оценки лекарственного средства (Летромара) // Журнал АМН Украины. — 2006. — Т. 12. — № 4. — С. 781–794.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
